Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
Takashi SasakiMasahiro SugawaraMasahiro FukudaPublished in: Journal of diabetes investigation (2018)
Luseogliflozin treatment brought about favorable changes in body composition and metabolism of moderately obese Japanese type 2 diabetes patients, accompanied by body fat reduction, and minimal muscle and BMC reduction.
Keyphrases
- body composition
- weight loss
- type diabetes
- resistance training
- bone mineral density
- end stage renal disease
- newly diagnosed
- ejection fraction
- bariatric surgery
- adipose tissue
- cardiovascular disease
- metabolic syndrome
- skeletal muscle
- glycemic control
- peritoneal dialysis
- patient reported
- weight gain
- patient reported outcomes
- gastric bypass
- smoking cessation
- double blind